Stock Events

Stock Events

Klaria Pharma AB 

€0.051800
3
+€0.00+0.19% 06:00 Today

Statistics

Day High
0.0518
Day Low
0.0518
52W High
0.1185
52W Low
0.0334
Volume
-
Avg. Volume
-
Mkt Cap
12.91M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

26NovExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-517.35%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
827,185.45Revenue
-4.28MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap7.95B
Alkermes plc develops similar pharmaceutical products focusing on central nervous system (CNS) diseases, competing in overlapping therapeutic areas.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. is a biotechnology firm that develops novel therapies, including for conditions treated by Klaria's products, making them direct competitors in biopharmaceuticals.
Biogen
BIIB
Mkt Cap32.28B
Biogen Inc. focuses on developing drugs for neurological diseases, directly competing with Klaria Pharma in the neurology pharmaceuticals market.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol-Myers Squibb Company operates in the global biopharmaceutical market, developing drugs that may compete with Klaria’s therapeutic solutions.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline plc produces pharmaceuticals across multiple therapeutic areas, including those targeted by Klaria, making them a broad competitor.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson engages in the research and development of pharmaceuticals that could directly compete with Klaria Pharma's product offerings.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly and Company is involved in pharmaceutical development for conditions that overlap with Klaria’s focus areas, particularly in CNS and pain management.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. develops a wide range of pharmaceutical products that could compete across several of Klaria’s key therapeutic areas.
Novartis
NVS
Mkt Cap292.35B
Novartis AG is a global healthcare company that develops medicines in various fields, including those in competition with Klaria Pharma.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. is a large pharmaceutical company with a diverse portfolio that includes products which could compete with Klaria Pharma’s treatments.

About

Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. Within its pipeline, Klaria is developing Epinephrine/Adrenaline to address severe allergic responses, Naloxone for reversing opioid overdoses, and Ketamine for applications in acute pain and mood disorders. Moreover, the company is actively involved in bringing cannabis/cannabinoid products, including THC and CBD, to market for medical and recreational purposes. Established in 2014, Klaria is headquartered in Uppsala, Sweden.
Show more...
CEO
Scott Boyer
Employees
4
Country
Sweden
ISIN
SE0007280326
WKN
000A14V7P

Listings

STU
DE
6FN.STU
ST
SE
KLAR-BTA.ST
MU
DE
6FN.MU
F
DE
6FN.F

0 Comments

Share your thoughts

FAQ

What is Klaria Pharma AB stock price today?▼
The current price of 6FN.F is €0.05 EUR — it has increased by +0.19% in the past 24 hours. Watch Klaria Pharma AB stock price performance more closely on the chart.
What is Klaria Pharma AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Klaria Pharma AB stocks are traded under the ticker 6FN.F.
Is Klaria Pharma AB stock price growing?▼
6FN.F stock has fallen by -41.6% compared to the previous week, the month change is a -22.57% fall, over the last year Klaria Pharma AB has showed a +15.11% increase.
What is Klaria Pharma AB market cap?▼
Today Klaria Pharma AB has the market capitalization of 12.91M
When is the next Klaria Pharma AB earnings date?▼
Klaria Pharma AB is going to release the next earnings report on November 26, 2026.
What is Klaria Pharma AB revenue for the last year?▼
Klaria Pharma AB revenue for the last year amounts to 827,185.45 EUR.
What is Klaria Pharma AB net income for the last year?▼
6FN.F net income for the last year is -4.28M EUR.
How many employees does Klaria Pharma AB have?▼
As of September 04, 2026, the company has 4 employees.
In which sector is Klaria Pharma AB located?▼
Klaria Pharma AB operates in the Health & Wellness sector.
When did Klaria Pharma AB complete a stock split?▼
Klaria Pharma AB has not had any recent stock splits.
Where is Klaria Pharma AB headquartered?▼
Klaria Pharma AB is headquartered in Uppsala, Sweden.